Related Experiment Video

Updated: May 8, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in

Zhiyuan Lou1, Tingting Ren, Xianbo Peng

  • 1Musculoskeletal Tumour Centre, People's Hospital, Peking University, Beijing, China.

The Journal of International Medical Research
|August 27, 2013
PubMed
Abstract

Insights

Bortezomib effectively inhibits osteosarcoma HOS cell growth, inducing apoptosis and autophagy. These effects are linked to changes in mitogen-activated protein kinase (MAPK) signaling pathways, suggesting bortezomib as a potential osteosarcoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Osteosarcoma is a primary bone malignancy with limited effective treatments.
  • Understanding the molecular mechanisms of novel therapeutic agents is crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the anti-cancer effects of bortezomib on human osteosarcoma HOS cells.
  • To elucidate the underlying molecular mechanisms, including cell cycle changes, apoptosis, autophagy, and MAPK signaling.

Main Methods:

  • Human osteosarcoma HOS cells were treated with varying concentrations of bortezomib.
  • Cell viability, cell cycle progression, apoptosis, and autophagy were assessed using assays like annexin V-FITC and Western blotting.
  • Mitogen-activated protein kinase (MAPK) pathway activation was analyzed via Western blotting.

Main Results:

  • Bortezomib demonstrated time- and dose-dependent inhibition of HOS cell growth.
  • Bortezomib induced apoptosis and autophagy in a dose-dependent manner.
  • Changes in MAPK signaling molecules (MEK1/2, ERK1/2, JNK, p38) correlated with bortezomib-induced apoptosis and autophagy.

Conclusions:

  • Bortezomib effectively induces apoptosis and autophagy in human osteosarcoma HOS cells.
  • The study provides insights into bortezomib's mechanism of action involving MAPK pathways.
  • Bortezomib shows potential as a chemotherapeutic agent for osteosarcoma treatment.
Keywords:
Apoptosisautophagybortezomibcell-cycle arrestmitogen-activated protein kinase (MAPK)osteosarcomaproteasome inhibitiontransmission electron microscopy (TEM)

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...